Pivotal pharmacokinetic clinical study for Riluzole Oral Soluble Film

Trial Profile

Pivotal pharmacokinetic clinical study for Riluzole Oral Soluble Film

Planning
Phase of Trial: Phase I

Latest Information Update: 09 Jan 2017

At a glance

  • Drugs Riluzole (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Pharmacokinetics
  • Most Recent Events

    • 09 Jan 2017 New trial record
    • 05 Jan 2017 According to a MonoSol Rx media release, the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) Application for Riluzole Oral Soluble Film (Riluzole OSF) for the treatment of Amyotrophic Lateral Sclerosis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top